NASDAQ · TPST
Healthcare · Biotechnology
$1.04
Up+$0.02 (+1.96%)
Updated Aug 23, 2026, 6:17 AM
SID Score
3.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
TPST closed at $1.04 after 20 trading sessions, up 11.28% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $1.02 | $1.08 | $1.00 | $1.04 | 133.86K |
| Aug 20, 2026 | $1.05 | $1.0748 | $1.005 | $1.02 | 89.58K |
| Aug 19, 2026 | $1.02 | $1.08 | $1.02 | $1.07 | 155.96K |
| Aug 18, 2026 | $1.11 | $1.11 | $1.0101 | $1.07 | 334.95K |
| Aug 17, 2026 | $1.09 | $1.17 | $1.045 | $1.13 | 818.48K |
| Aug 14, 2026 | $1.12 | $1.12 | $0.9942 | $1.015 | 435.16K |
| Aug 13, 2026 | $1.20 | $1.2082 | $1.08 | $1.17 | 286.73K |
| Aug 12, 2026 | $1.20 | $1.24 | $1.16 | $1.21 | 388.48K |
| Aug 11, 2026 | $1.09 | $1.26 | $1.06 | $1.18 | 1.78M |
| Aug 10, 2026 | $0.9499 | $1.1091 | $0.9418 | $1.04 | 449K |
| Aug 7, 2026 | $0.91 | $0.93 | $0.9024 | $0.9167 | 87.49K |
| Aug 6, 2026 | $0.91 | $0.936 | $0.9002 | $0.9024 | 26.12K |
| Aug 5, 2026 | $0.90 | $0.9351 | $0.8852 | $0.9143 | 99.8K |
| Aug 4, 2026 | $0.8668 | $0.9036 | $0.8668 | $0.8872 | 67.87K |
| Aug 3, 2026 | $0.89 | $0.8999 | $0.8748 | $0.8751 | 104.31K |
| Jul 31, 2026 | $0.8829 | $0.8878 | $0.8526 | $0.8563 | 69.51K |
| Jul 30, 2026 | $0.8924 | $0.9001 | $0.86 | $0.8637 | 42.24K |
| Jul 29, 2026 | $0.85 | $0.921 | $0.8401 | $0.8924 | 158.7K |
| Jul 28, 2026 | $0.9363 | $0.9587 | $0.871 | $0.871 | 151.26K |
| Jul 27, 2026 | $0.9052 | $0.9784 | $0.905 | $0.9346 | 127.85K |
The latest Smart Investors Daily articles mentioning TPST.
TPST research
Company profile and research snapshot.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jan 22, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 10, 2025 | Scotiabank | Sector Perform | — |
| Apr 10, 2025 | HC Wainwright & Co. | Neutral | — |
| Mar 28, 2025 | Scotiabank | Sector Outperform | — |
| Mar 28, 2025 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 13, 2026
On August 13, 2026, Tempest Therapeutics, Inc., a Delaware corporation (the "Company"), entered into a purchase agreement (the "Purchase Agreement") and a registration rights agreement (the
Benzinga · Aug 13, 2026
Tempest Therapeutics (NASDAQ:TPST) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.30) by 13.33 percent. This is a 83.57 percent increase over losses of $(2.07) per
Benzinga · Jul 21, 2026
Tempest’s TPST-4003 is a next-generation in vivo CAR-T candidate combining proprietary CD7-targeted mRNA/LNP delivery with a dual-target CD19/BCMA CAR construct designed to enable broad B-cell lineage depletion and
Benzinga · Jul 15, 2026
Advancing a pipeline of in vivo CAR-T product candidates for oncology and immunology applications differentiated by CD7-targeted mRNA/LNP delivery approachLead candidate TPST-4003 combines proprietary CD7-targeted
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning TPST.
